Parkinson’s Disease

Treatment approaches covered
- Pharmacotherapy
- Behavioral therapy
- Exercise-based therapy
- Deep brain stimulation
- Infusion/injection-based delivery

Details

1. Includes cognitive impairment, hallucinations and psychosis, depressed mood, anxious mood, apathy, and features of dopamine dysregulation syndrome
2. Includes sleep problems, daytime sleepiness, pain and other sensations, urinary problems, constipation problems, light headedness on standing, fatigue, sweating, and sexual function
3. Includes speech, saliva and drooling, chewing and swallowing, eating tasks, dressing, hygiene, handwriting, doing hobbies and other activities, turning in bed, tremor, getting out of a bed, a car, or a deep chair, walking and balance, and freezing
4. Recommended to track via the Parkinson’s Disease Quality of Life Questionnaire (PDQ-8)

For a complete overview of this Set, including definitions for each measure, time points for collection, and associated risk factors, visit ichom.org/medical-conditions/Parkinsons-Disease

© 2023 ICHOM. All rights reserved. When using this set of outcomes, or quoting therefrom, in any way, we solely require that you always make a reference to ICHOM as the source so that this organization can continue its work to define more Sets of Patient-Centered Outcome Measures. Version 4.0.0 Revised: January 2022
The ICHOM Set is the result of hard work by a group of leading physicians, measurement experts and patients together with the non-profit organization ICHOM. It represents the outcomes that matter most to patients with Parkinson’s disease. We urge all providers around the world to start measuring these outcomes to better understand how to improve the lives of the patients they serve.

The Process

The Working Group

Canada
Connie Marras | University of Toronto

Germany
Richard Dodel | Philipps-Universität Marburg

Italy
Angelo Antonini | IRCCS San Camillo, Venice

Netherlands
Bas Bloem | Radboud University Nijmegen Medical Center

Spain
Pablo Martinez-Martin | National Center of Epidemiology and CIBERNED

Sweden
Peter Hagell | Kristianstad University

Per Odin | Skåne University Hospital
Paul de Roos | Uppsala University Hospital

United Kingdom
K Ray Chaudhuri | King’s College, London

United States
Shyamal Mehta | Mayo Clinic
Ryan Uitti | Mayo Clinic

Daniel Weintraub | Hospital of the University of Pennsylvania
Bill Wilson* | Parkinson’s Disease Foundation

*Patient representative